CHANGING THE WAY WE MAKE
AND TAKE MEDICINES
STEERLife is a unique synergy between engineering and pharmaceutical sciences to create technologies that effectively replace conventional batch processing with true continuous manufacturing and help develop advanced effervescent and other unique drug delivery platforms.
Scroll right to see how STEERLife is revolutionising the batch to continuous (B2C) paradigm
MOVING FROM
‘SWALLOWING’ TO ‘SIPPING’
CLICK HERE TO FIND OUT MORE
<
>
WORK WITH US
Drug Development
Manufacturing Solutions
- Create novel formulations with distinct pharmacokinetic, therapeutic and manufacturability benefits
- Develop the full dossier for these novel medicines, licenses them to commercial organizations and shares in the sales success
- Focus on high value specialty markets including 'First To File" Generics/Lone generics
- Fast to market opportunities in the OTC and Nutraceutical markets
- Equipment improves Continuous Manufacturing technology and enables lower costs of product development and manufacturing
- Top twenty Pharma companies will buy complete systems from system providers
- Develop OEM partnership with key suppliers to sell to big pharma
- Sell directly to the rest of the market: Pharma companies and CDEMOs
- Sell/License the equipment and restrict its use to specific applications
IN THE NEWS
STEERLife Partners With Center for Structured Organic Particulate Systems (C-SOPS) USA
Bio Space, April 18, 2018
PUBLICATIONS
DOWNLOADS
IT'S TIME TO CHANGE
“Right now, manufacturing experts from the 1950s would easily recognize the pharmaceutical manufacturing processes of today. It is predicted that manufacturing will change in the next 25 years as current manufacturing practices are abandoned in favor of cleaner, flexible, more efficient continuous manufacturing”
Dr. Janet Woodcock
M.D., Director, USFDA, Center for Drug Evaluation and Research
“The whole industry is discussing continuous manufacturing. The other issue related to mindset is that companies have to change the way they are doing Process R&D, and that takes effort”
Bernhardt Trout
Director of the Novartis-MIT Center for Continuous Manufacturing
“I don’t know why it’s not more widely used as this is the future.”
Dr. Janet Woodcock
M.D., Director, USFDA, Center for Drug Evaluation and Research